High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors.

Maleki Vareki S. · 2018

Read High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. by Maleki Vareki S. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6307306.txt.

Description

Maleki Vareki argues that two tumor labels must be read together to predict drug response. The article appeared in the Journal for ImmunoTherapy of Cancer. Some tumors are called hot because immune cells crowd inside them. Others are cold, with few immune cells present. A second label counts total mutations in the tumor. High counts can create more targets for immune attack.

Neither label alone explains who benefits from checkpoint drugs. Melanoma and lung tumors are often hot and responsive. Prostate and pancreatic tumors are cold and rarely respond. Some cases break the simple pattern, though. The author urges judging tumors by both traits. That pairing should better pick patients for immunotherapy.

Catalog record

CREATORMaleki Vareki S.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE21 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6307306

Browse the full library · About the Tower of Babel